180 related articles for article (PubMed ID: 19521033)
1. [Pharmacological properties and clinical efficacies of tazobactam/piperacillin (Zosyn 2.25, Zosyn 4.5), an injectable antibiotic combined with beta-lactamase inhibitor].
Uji T; Hashimoto Y
Nihon Yakurigaku Zasshi; 2009 Jun; 133(6):351-8. PubMed ID: 19521033
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic evaluation of piperacillin-tazobactam.
Hayashi Y; Roberts JA; Paterson DL; Lipman J
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1017-31. PubMed ID: 20636224
[TBL] [Abstract][Full Text] [Related]
3. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination.
Gin A; Dilay L; Karlowsky JA; Walkty A; Rubinstein E; Zhanel GG
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):365-83. PubMed ID: 17547502
[TBL] [Abstract][Full Text] [Related]
4. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
5. [Clinical studies of tazobactam/piperacillin (TAZ/PIPC) in pediatric patients].
Waga S; Yokoyama M; Tsushima T; Chiba C; Saito T; Okamoto T; Asuka T; Kitazawa J; Tateyama N; Sato Y; Takahashi Y
Jpn J Antibiot; 1998 May; 51(5):305-18. PubMed ID: 9693964
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetic and clinical evaluation of tazobactam/piperacillin in the pediatric field].
Toyonaga Y; Ishihara T; Tezuka T; Nakamura H
Jpn J Antibiot; 1998 May; 51(5):325-45. PubMed ID: 9693966
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of ertapenem.
Teppler H; Gesser RM; Friedland IR; Woods GL; Meibohm A; Herman G; Mistry G; Isaacs R
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii75-81. PubMed ID: 15150186
[TBL] [Abstract][Full Text] [Related]
8. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
[TBL] [Abstract][Full Text] [Related]
9. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.
Jones RN; Fritsche TR; Moet GJ
Diagn Microbiol Infect Dis; 2008 May; 61(1):76-9. PubMed ID: 18221852
[TBL] [Abstract][Full Text] [Related]
10. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
[TBL] [Abstract][Full Text] [Related]
11. [Drugs: piperacillin/tazobactam].
Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):132-3. PubMed ID: 7711129
[No Abstract] [Full Text] [Related]
12. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of beta-lactamase inhibitors in combination with extended-spectrum penicillins.
Jones RN
Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S29-33. PubMed ID: 7606587
[TBL] [Abstract][Full Text] [Related]
14. Is the Combination of Piperacillin-Tazobactam and Vancomycin Associated with Development of Acute Kidney Injury? A Meta-analysis.
Giuliano CA; Patel CR; Kale-Pradhan PB
Pharmacotherapy; 2016 Dec; 36(12):1217-1228. PubMed ID: 27805728
[TBL] [Abstract][Full Text] [Related]
15. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
Attivi D; Gibaud S
Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
[TBL] [Abstract][Full Text] [Related]
16. Piperacillin-Tazobactam-induced Adverse Drug Events in Pediatric Patients on Outpatient Parenteral Antimicrobial Therapy.
Yusef D; Gonzalez BE; Foster CB; Goldfarb J; Saracusa C; Worley S; Sabella C
Pediatr Infect Dis J; 2017 Jan; 36(1):50-52. PubMed ID: 27749652
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
Falagas ME; Tansarli GS; Ikawa K; Vardakas KZ
Clin Infect Dis; 2013 Jan; 56(2):272-82. PubMed ID: 23074314
[TBL] [Abstract][Full Text] [Related]
18. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
[TBL] [Abstract][Full Text] [Related]
20. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers.
Stiefel U; Paterson DL; Pultz NJ; Gordon SM; Aron DC; Donskey CJ
Infect Control Hosp Epidemiol; 2004 May; 25(5):380-3. PubMed ID: 15188842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
